

Consolidated balance sheet

in CHF 1 000	Notes	31.03.2025	31.12.2024
Current assets			
Cash and cash equivalents		70 177	458
Receivables from brokers		19 339	–
Securities	3	1 859 297	2 406 881
Other assets		57	60
		1 948 870	2 407 399
Total assets		1 948 870	2 407 399
Current liabilities			
Short-term borrowings from banks	4	–	117 500
Payables to brokers		908	–
Other short-term liabilities		3 402	3 513
Tax liabilities		107	94
		4 417	121 107
Total liabilities		4 417	121 107
Shareholders' equity			
Share capital	5	11 080	11 080
Treasury shares	5	(42 058)	(39 640)
Retained earnings		1 975 431	2 314 852
		1 944 453	2 286 292
Total liabilities and shareholders' equity		1 948 870	2 407 399
Net asset value per share in CHF		35.55	41.75

The notes are an integral part of the condensed consolidated interim financial statements.

The condensed consolidated interim financial statements were approved by the Board of Directors of BB Biotech AG on April 22, 2025.

Consolidated statement of comprehensive income

in CHF 1 000	Notes	01.01.–31.03.2025	01.01.–31.03.2024
Operating income			
Gains from securities	3	–	270 709
Interest income		108	–
Other income		1 279	5
		1 387	270 714
Operating expenses			
Losses from securities	3	(233 336)	–
Interest expenses		(55)	(1 435)
Foreign exchange losses		(1 459)	(16)
Administrative expenses	6	(6 076)	(7 525)
Other expenses		(1 380)	(1 225)
		(242 306)	(10 201)
Profit/(loss) before tax	7	(240 919)	260 513
Income taxes		(15)	(19)
Profit/(loss) for the period		(240 934)	260 494
Total comprehensive profit/(loss) for the period		(240 934)	260 494
Earnings per share in CHF	8	(4.40)	4.75
Diluted earnings per share in CHF	8	(4.40)	4.75

The notes are an integral part of the condensed consolidated interim financial statements.

Consolidated statement of changes in equity

in CHF 1 000	Share capital	Treasury shares	Retained earnings	Total
Balances at January 1, 2024	11 080	(36 508)	2 348 645	2 323 217
Dividend (CHF 2.00 per share)	–	–	(109 692)	(109 692)
Total comprehensive income for the period	–	–	260 494	260 494
Balances at March 31, 2024	11 080	(36 508)	2 499 447	2 474 019
Balances at January 1, 2025	11 080	(39 640)	2 314 852	2 286 292
Dividend (CHF 1.80 per share)	–	–	(98 487)	(98 487)
Trade with treasury shares	–	(2 418)	–	(2 418)
Total comprehensive income for the period	–	–	(240 934)	(240 934)
Balances at March 31, 2025	11 080	(42 058)	1 975 431	1 944 453

The notes are an integral part of the condensed consolidated interim financial statements.

Consolidated statement of cash flows

in CHF 1 000	Notes	01.01.–31.03.2025	01.01.–31.03.2024
Cash flows from operating activities			
Proceeds from sales of securities	3	389 953	161 515
Purchase of securities	3	(94 618)	(81 566)
Interest receipts		108	–
Other proceeds		1 279	–
Payments for services		(7 567)	(8 667)
Income taxes paid		–	(35)
Total cash flows from operating activities		289 155	71 247
Cash flows from financing activities			
Dividend		(98 487)	(109 692)
Purchase of treasury shares	5	(1 935)	–
Proceeds from borrowings	4	–	39 800
Repayment of borrowings	4	(117 500)	–
Interest payments		(55)	(1 435)
Total cash flows from financing activities		(217 977)	(71 327)
Foreign exchange difference		(1 459)	(16)
Change in cash and cash equivalents		69 719	(96)
Cash and cash equivalents at the beginning of the period		458	501
Cash and cash equivalents at the end of the period		70 177	405

The notes are an integral part of the condensed consolidated interim financial statements.

Notes to the consolidated financial statements

1. The Company and its principal activity

BB Biotech AG (the Company) is listed on the SIX Swiss Exchange as well as in the «Prime Standard Segment» of the German Exchange and has its registered office in Schaffhausen, Schwertstrasse 6. Its principal activity is to invest in companies active in the biotechnology industry for the purpose of capital appreciation. The investments are held through its wholly owned subsidiaries.

Company	Capital in CHF 1 000	Capital and voting interest in %
Biotech Focus N.V., Curaçao	11	100
Biotech Growth N.V., Curaçao	11	100
Biotech Invest N.V., Curaçao	11	100
Biotech Target N.V., Curaçao	11	100

2. Accounting policies

The condensed consolidated interim financial statements of the Company and its subsidiary companies (the Group) have been prepared in accordance with International Accounting Standards (IAS) 34 «Interim Financial Reporting,» as well as the provisions of the rules of the SIX Swiss Exchange for Investment Companies and should be read in conjunction with the consolidated annual financial statements for the year ended December 31, 2024. The preparation of the condensed consolidated interim financial statements requires management to make assumptions and estimates that have an impact on the balance sheet values and items of the statement of comprehensive income in the current financial period. In certain circumstances, the actual values may diverge from these estimates.

The condensed consolidated interim financial statements have been prepared in accordance with the accounting policies set out in the consolidated annual financial statements.

The following amended standard, valid since January 1, 2025, has been applied in these condensed consolidated interim financial statements:

- IAS 21 (amended, effective January 1, 2025) – Lack of Exchangeability

The following new and amended standards were approved, but will only be applicable for the Group prospectively and were not early adopted in these condensed consolidated interim financial statements:

- IFRS 9/IFRS 7 (amended, effective January 1, 2026) – Classification and Measurement of Financial Instruments
- IFRS 18 (effective January 1, 2027) – Presentation and Disclosure in Financial Statements
- IFRS 19 (effective January 1, 2027) – Subsidiaries without Public Accountability: Disclosures

The Group assessed the potential impact of the above-mentioned new and amended standards. Based on the analysis, the Group concludes that these new and amended standards have no material impact on the Group's accounting policies and overall results and financial position.

The following exchange rates have been used for the preparation of these condensed consolidated interim financial statements:

Currency	31.03.2025	31.12.2024
USD	0.88430	0.90740
ANG	0.49680	0.50978
EUR	0.95637	0.94008
GBP	1.14230	1.13560

3. Financial assets

Fair Values

The following table presents the Group's assets that are measured at fair value (in CHF 1 000):

31.03.2025	Level 1	Level 2	Level 3	Total
Assets				
Securities				
- Shares	1 811 082	-	48 215	1 859 297
- Derivative instruments	-	-	-	-
Total assets	1 811 082	-	48 215	1 859 297
31.12.2024				
Assets				
Securities				
- Shares	2 369 436	-	37 444	2 406 881
- Derivative instruments	-	-	-	-
Total assets	2 369 436	-	37 444	2 406 881

The table below summarizes the transactions in level 3 instruments (in CHF 1 000):

	01.01.–31.03.2025	01.01.–31.03.2024
Opening balance	37 444	14 725
Purchases	12 079	-
Unrealized gains/(losses) included in gains/losses from securities	(1 309)	1 050
Closing balance	48 215	15 775
Gains/(losses) on level 3 instruments included in gains/losses from securities	(1 309)	1 050

There were no transfers between level 1, 2 and 3 during the reporting period.

The fair value of level 3 instruments at initial recognition represents the transaction price (purchase of preferred stocks of Rivos Pharmaceuticals in August 2022 for TCHF 16 875, August 2024 for TCHF 15 139 and January 2025 for TCHF 12 079), which was paid in financing rounds together with other investors. For the valuation as at March 31, 2025, it is deemed to be appropriate to use the latest transaction price in USD, as it is a reasonable approximation of fair value at the valuation date given the fact that no events occurred which significantly impact the fair value.

In August 2022, 8 733 538 Radius Health – Contingent Value Rights were allocated from a corporate action. In February 2025 BB Biotech received USD 1 per Right.

For assets and liabilities carried at amortised cost, their carrying values are a reasonable approximation of fair value.

Securities

The changes in value of securities at fair value through profit or loss by investment category are as follows (in CHF 1 000):

	Listed shares	Unlisted shares	Derivative instruments	Total
Opening balance as at 01.01.2024 at fair values	2 619 989	14 725	–	2 634 714
Purchases	206 303	15 139	316	221 758
Sales	(561 097)	–	(42)	(561 139)
Gains/(losses) from securities	104 241	7 581	(274)	111 548
<i>Realized gains</i>	<i>107 900</i>	–	–	<i>107 900</i>
<i>Realized losses</i>	<i>(46 182)</i>	–	<i>(274)</i>	<i>(46 456)</i>
<i>Unrealized gains</i>	<i>480 172</i>	<i>7 581</i>	–	<i>487 753</i>
<i>Unrealized losses</i>	<i>(437 649)</i>	–	–	<i>(437 649)</i>
Closing balance as at 31.12.2024 at fair values	2 369 436	37 444	–	2 406 881
Opening balance as at 01.01.2025 at fair values	2 369 436	37 444	–	2 406 881
Purchases	82 965	12 079	–	95 044
Sales	(401 392)	–	(7 900)	(409 292)
Gains/(losses) from securities	(239 927)	(1 309)	7 900	(233 336)
<i>Realized gains</i>	<i>115 331</i>	–	<i>7 900</i>	<i>123 231</i>
<i>Realized losses</i>	<i>(28 970)</i>	–	–	<i>(28 970)</i>
<i>Unrealized gains</i>	<i>44 523</i>	–	–	<i>44 523</i>
<i>Unrealized losses</i>	<i>(370 811)</i>	<i>(1 309)</i>	–	<i>(372 120)</i>
Closing balance as at 31.03.2025 at fair values	1 811 082	48 215	–	1 859 297

Securities comprise the following:

Company	Number 31.12.2024	Change	Number 31.03.2025	Market price in original currency 31.03.2025	Valuation CHF mn 31.03.2025	Valuation CHF mn 31.12.2024	
Argenx SE	591 000	(15 000)	576 000	USD	591.87	301.5	329.8
Ionis Pharmaceuticals	7 850 000	–	7 850 000	USD	30.17	209.4	249.0
Alnylam Pharmaceuticals	760 000	–	760 000	USD	270.02	181.5	162.3
Neurocrine Biosciences	1 820 000	–	1 820 000	USD	110.60	178.0	225.4
Vertex Pharmaceuticals	475 000	(75 000)	400 000	USD	484.82	171.5	173.6
Revolution Medicines	4 374 300	–	4 374 300	USD	35.36	136.8	173.6
Incyte	2 150 000	(62 698)	2 087 302	USD	60.55	111.8	134.7
Agios Pharmaceuticals	3 515 150	–	3 515 150	USD	29.30	91.1	104.8
Scholar Rock Holding	2 486 707	–	2 486 707	USD	32.15	70.7	97.5
Celldex Therapeutics	3 071 615	–	3 071 615	USD	18.15	49.3	70.4
Akero Therapeutics	–	1 250 666	1 250 666	USD	40.48	44.8	–
Biohaven	2 040 853	–	2 040 853	USD	24.04	43.4	69.2
Beam Therapeutics	1 518 121	877 809	2 395 930	USD	19.53	41.4	34.2
Moderna	1 600 000	(91 423)	1 508 577	USD	28.35	37.8	60.4
Immunocore	1 205 464	16 330	1 221 794	USD	29.67	32.1	32.3
Wave Life Sciences	4 094 458	–	4 094 458	USD	8.08	29.3	46.0
Edgewise Therapeutics	1 428 929	–	1 428 929	USD	22.00	27.8	34.6
Relay Therapeutics	7 375 000	–	7 375 000	USD	2.62	17.1	27.6
Esperion Therapeutics	9 944 064	(250 000)	9 694 064	USD	1.44	12.3	19.9
Macrogenics	9 929 963	–	9 929 963	USD	1.27	11.2	29.3
Annexon	5 157 290	–	5 157 290	USD	1.93	8.8	24.0
Black Diamond Therapeutics	8 517 839	(5 784 292)	2 733 547	USD	1.55	3.7	16.5
Intra-Cellular Therapies	2 425 000	(2 425 000)	–	USD	131.92	–	183.8
Arvinas	2 380 000	(2 380 000)	–	USD	7.02	–	41.4
Sage Therapeutics	4 460 693	(4 460 693)	–	USD	7.95	–	22.0
Fate Therapeutics	4 839 779	(4 839 779)	–	USD	0.79	–	7.2
Listed shares						1 811.1	2 369.5
Rivus Pharmaceuticals				USD		48.2	37.4
Unlisted shares						48.2	37.4
Total shares						1 859.3	2 406.9
Molecular Templates – Warrants, 2.4.29	769 334	–	769 334	USD	0.00	0.0	–
Radius Health – Contingent Value Right	8 733 538	(8 733 538)	–	USD	0.00	0.0	–
Total derivative instruments						–	–
Total securities						1 859.3	2 406.9

4. Short-term borrowings from banks

At March 31, 2025, there is no short-term loan outstanding (December 31, 2024: CHF 117.5 mn at 0.90% p.a.).

5. Shareholders' equity

The share capital of the Company consists of 55.4 mn fully paid registered shares (December 31, 2024: 55.4 mn) with a par value of CHF 0.20 each (December 31, 2024: CHF 0.20).

Treasury shares

The Company can buy and sell treasury shares in accordance with the Company's articles of association and Swiss company law and in compliance with the listing rules of the SIX Swiss

Exchange. During the period from January 1, 2025, to March 31, 2025, the Company has bought 70 750 treasury shares and has not sold any treasury shares (01.01.–31.03.2024: no transactions). As at March 31, 2025, the Company holds 708 750 treasury shares (December 31, 2024: 638 000 shares). The treasury shares as at March 31, 2025, were treated as a deduction from the consolidated shareholders' equity using cost values of TCHF 42 058 (December 31, 2024: TCHF 39 640).

Share buyback 2nd line (bought for cancellation)

The Board of Directors has approved the repurchase of a maximum of 5 540 000 own registered shares with a nominal value of CHF 0.20 each. Until the end of the program at April 11, 2025, 250 750 registered shares were repurchased via a second trading line for the purpose of capital reduction. Until March 31, 2025, 154 750 shares had been repurchased under this share buy-back program (December 31, 2024: 84 000 shares).

6. Administrative expenses

Administrative expenses comprise the following:

in CHF 1 000	01.01.–31.03.2025	01.01.–31.03.2024
Investment manager		
– Management fees	5 527	6 996
Personnel		
– Board of Directors remuneration	415	420
– Wages and salaries	88	70
– Social insurance contributions and duties	46	39
	6 076	7 525

The remuneration model of BB Biotech AG is determined by the Board of Directors.

Since 2014 the remuneration paid to the investment manager is based upon a 1.1% p.a. all-in fee on the average market capitalization without any additional fixed or performance-based elements of compensation. The compensation of the Board of Directors consists since 2014 of a fixed compensation.

7. Segment reporting

The sole operating segment of the Group reflects the internal management structure and is evaluated on an overall basis. Revenue is derived by investing in a portfolio of companies active in the biotechnology industry for the purpose of capital appreciation. The following results correspond to the sole operating segment of investing in companies active in the biotechnology industry.

The geographical analysis of the profit/(loss) before tax is as follows – all income from financial assets are attributed to a country based on the domiciliation of the issuer of the instrument.

Profit/(loss) before tax in CHF 1 000	01.01.–31.03.2025	01.01.–31.03.2024
Canada	–	16 544
Great Britain	(638)	1 069
Switzerland	(2 631)	5 755
Curaçao	(6 226)	(8 884)
Singapore	(16 703)	6 108
Netherlands	(19 739)	27 903
British Virgin Islands	(25 782)	15 237
USA	(169 200)	196 780
	(240 919)	260 513

8. Earnings per share

	01.01.–31.03.2025	01.01.–31.03.2024
Total comprehensive profit/(loss) for the period (in CHF 1 000)	(240 934)	260 494
Weighted average number of shares in issue	54 738 625	54 846 000
Earnings per share in CHF	(4.40)	4.75
Income used to determine diluted earnings per share (in CHF 1 000)	(240 934)	260 494
Weighted average number of shares in issue following the dilution	54 738 625	54 846 000
Diluted earnings per share in CHF	(4.40)	4.75

9. Assets pledged

At March 31, 2025, securities in the amount of CHF 1 859.3 mn (December 31, 2024: CHF 2 406.9 mn) are collateral for a credit line of CHF 700 mn (December 31, 2024: CHF 700 mn). At March 31, 2025, there is no short-term loan outstanding (December 31, 2024: CHF 117.5 mn).

10. Transactions with the Investment Manager and related party transactions

Detailed information regarding the remuneration model for the Board of Directors and the investment manager are mentioned under note «6. Administrative Expenses».

11. Commitments, contingencies and other off-balance sheet transactions

The Group had no commitments or other off-balance sheet transactions open at March 31, 2025 and December 31, 2024.

The operations of the Group are affected by legislative, fiscal and regulatory developments for which provisions are made where deemed necessary. The Board of Directors concludes that as at March 31, 2025, no proceedings existed which could have any material effect on the financial position of the Group (December 31, 2024: none).

12. Subsequent events

There have been no events subsequent to March 31, 2025, which would affect the condensed consolidated interim financial statements.

Report on the review of condensed consolidated interim financial statements

Introduction

In accordance with the terms of our engagement, we have reviewed the condensed consolidated interim financial statements (consolidated balance sheet, consolidated statement of comprehensive income, consolidated statement of changes in equity, consolidated statement of cash flows and selected explanatory notes) of BB Biotech AG for the period ended 31 March 2025.

These condensed consolidated interim financial statements in accordance with International Accounting Standard 34 «Interim Financial Reporting» and article 14 of the Directive on Financial Reporting of the SIX Swiss Exchange are the responsibility of the Board of Directors whereas our responsibility is to issue a report on these condensed consolidated interim financial statements based on our review.

Scope of Review

We conducted our review in accordance with the Swiss Auditing Standard 910 (SAS 910) «Engagements to Review Financial Statements» and the International Standard on Review Engagements (ISRE) 2410 «Review of interim financial information performed by the independent auditor of the entity». This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the condensed consolidated interim financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements do not give a true and fair view of all material respects of the net assets, the financial position and results of operations in accordance with International Accounting Standard 34 Interim Financial Reporting and article 14 of the Directive on Financial Reporting of the SIX Swiss Exchange.

Deloitte AG

Chris Krämer
Audit expert
Auditor in charge

Mathieu Valette
Audit expert

Zurich, 23 April 2025

Deloitte AG, Pfingstweidstrasse 11, CH-8005 Zurich
Phone: +41 (0)58 279 60 00, Fax: +41 (0)58 279 66 00, www.deloitte.ch